{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Percentage change in the amount of myeloid derived suppressor cells (MDSCs) in peripheral blood.","groups":[{"description":"Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)\n\nTadalafil: Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days\n\nLenalidomide: Lenalidomide will be administered as it was prior to study entry.\n\nDexamethasone: Dexamethasone will be administered as it was prior to study entry.\n\nClarithromycin: Clarithromycin will be administered as it was prior to study entry.","id":"OG000","title":"Tadalafil"}],"populationDescription":"Data was not collected to assess this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Effect of PDE5 Inhibition on Immune Function as Assessed by MDSC Quantification","type":"SECONDARY"}